Korean biotech firm tees up W205bn listing
SillaJen Biotherapeutics is planning to go public with an eye to raise W205bn ($179.4m), according to a termsheet seen by GlobalCapital Asia.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: